Table 3. Lipid levels and CVD outcome in RA patients across different APOE genotype groups.

	APOE genotype group			Univariate			Multivariate
	ε2 carrier	ε3/ε3 carrier	ε4 carrier	Over all	ε2 vs. ε3/ε3	ε4 vs. ε3/ε3	Over all	ε2 vs. ε3/ε3	ε4 vs. ε3/ε3
	n = 15	n = 81	n = 40	p	p*	p*	p	p*	p*
TC	5.02 (1.33)	5.68 (1.08)	6.06 (1.52)	0.03	0.13	0.22	0.001	0.019	0.040
LDL	2.77 (1.24)	3.32 (0.87)	3.69 (1.31)	0.02	0.14	0.15	0.002	0.047	0.040
HDL	1.63 (0.49)	1.79 (0.57)	1.88 (0.65)	0.37	–	–	0.09	–	–
Triglycerides	1.40 (0.74)	1.24 (0.77)	1.27 (0.58)	0.75	–	–	0.67	–	–
IMT	0.77 (0.18)	0.78 (0.19)	0.75 (0.17)	0.66	–	–	0.14	–	–
Plaques	7 [46.7]	43 [55.1]	27 [67.5]	0.28	–	–	0.29	–	–
CVD event	1 [6.7]	14 [17.3]	8 [20.0]	0.59$	–	–	0.62	–	–
CVD/plaque	7 [46.7]	49 [61.3]	27 [67.5]	0.36	–	–	0.38	–	–

LDL: low density lipoproteins, HDL; High density lipoproteins, IMT; intima-media thickness (mm), CVD event; cardiovascular disease event (see Methods sections). All lipids are measured in mmol/L. Lipid levels and IMT were compared using ANCOVA, and unadjusted mean values with standard deviation (sd) are given in column 2, 3 and 4. CVD outcomes, which included previous CVD events or carotid plaques present on ultrasound (or both) were compared using Chi-square test; and the number of individuals affected with percentages [%] are given in column 2, 3 and 4. Multivariate analyses were adjusted for age, sex and current statin use. Not all patients had data on all variables and patients with genotype ε2/ε4 (n = 4) were omitted from the analyses.

^*p-values were corrected for multiple testing using Dunnets-Hsu adjustment.

^$Exact test.